Статья
ТРЕПЕТАНИЕ ПРЕДСЕРДИЙ: СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ДИАГНОСТИКИ И ЛЕЧЕНИЯ
Диагностика и лечение трепетания предсердий (ТП) является актуальной проблемой. Представлены данные эпидемиологии, электрофизиологические механизмы и современная классификация ТП, алгоритм лечения, который предложен ведущими экспертами. Показано, что в лечении ТП, как и при лечении фибрилляции предсердий (ФП), можно выделить 2 стратегии: «контроль ритма» и «контроль частоты». Отмечено, что снижение частоты желудочковых сокращений у больных с ТП, значительно труднее, чем при ФП. Описаны показания к различным видам терапии ТП: фармакологической терапии, электрокардиостимуляции и электроимпульсной терапии, а также к хирургическим методам лечения.
1. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. J Am Coll Cardiol 2003;42(8):1493-531.
2. Bialy D., Lehmann M.H., Schumacher D.N. et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation (abstr). J Am Coll Cardiol 1992; 19: 41A.
3. Granada J., Uribe W., Chyou P.H. et al. Incidence and predictor of atrial flutter in general population. J Am Coll Cardiol 2000; 36(7): 2242-2246.
4. Lee K.W., Yang Y., Scheinman M.M. Atrial flutter: a review of its history, mechanisms, clinical features and current therapy. Curr Probl Cardiol 2005;30(3):121-67.
5. Vidaillet H., Granada J.F., Chyou P.H. et al. A population-based of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113(5): 365-370.
6. Scheinman M.M., Yang Y., Cheng J. Atrial flutter: part II. Nomenclature. Pacing Clin Electrophysiol 2004; 27(4): 504-506.
7. Nakagawa H., Shah N., Matsudaira K. et al. Characterization of reentrant circuit in macroreentrant right atrial tachycardia after surgical repair of congential heart disease. Circulation 2001; 103(5): 699-709.
8. Jais P., Shah D.C., Haissaguerre M. et al. Mapping and ablation of left atrial flutters. Circulation 2000; 101(25): 2928-2934.
9. Kastor J.A., eds. Arrhythmias. Philadelphia: W.B. Saunders company;1994.p. 105-115.
10. Schreck D.M., Rivera A.R., Tricarico V.J. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997; 29(1): 135-140.
11. Goldenberg I.F., Lewis W.R., Dias V.C. et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994; 74(9): 884-889.
12. Grijns H.J., Van Gelder I.C., Tieleman R.G. et al. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart 1997; 77(1): 56-61.
13. Gallay P., Bertinchant J.P., Lehujeur C. et al. La stimylation transoesophagiennedans le traitement du flutter et de la tachysystolie auriculaire. Arch Mal Coeur 1985; 78(3): 311-316.
14. Stambler B.S., Wood M.A., Ellenbogen K.A. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996; 77(11): 960-966.
15. Doni F., Della Bella P., Kheir A. et al. Atrial flutter termination by overdrive trans-esophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 1995; 76(17): 1243-1246.
16. Volgman A.S., Carberry P.A., Stambler B. et al. Conversion efficacy and safety on intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am CollCardiol 1998; 31(6): 1414-1419.
17. Vos M.A., Golitsyn S.R., Stangl K. et al. Superiority of ibutilide over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 1998; 79(6): 568-575.
18. Rosenshtraukh L.V., Ruda M.Ia., Golitsyn S.P., Maikov E.B. Novel antiarrhythmic class III drug nibentan: from experimental studies to clinical practice. Kardiologiia. 2003;43(6):66-8. Russian (Розенштраух Л.В., Руда М.Я., Голицин С.П., Майков Е.Б. Новый отечественный антиаритмический препарат III класса нибентан: от экспериментальных исследований к клинической практике. Кардиология 2003; 43: 66-68).
19. Singh S., Zoble R.G., Yellen L. et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation of atrial flutter (SAFIRE-D study). Circulation 2000; 102(19): 2385-2390.
20. Pedersen O.D., Bagger H., Keller N. et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter with reduced left ventricular function (DIAMOND substudy). Circulation 2001; 104(3): 292-296.
21. Schumacher B., Jung W., Lewalter T. et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999; 83(5): 710-713.
22. Tai C.T., Chiang C.E., Lee S.H. et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone. J Cardiovasc Electrophysiol 1999; 10(9): 1180-1187.
23. Bunin Yu.A., Fedyakina L.F. Combined preventive anti-arrhythmic pharmacotherapy of atrial fibrillation and flutter. Rossiyskiy kardiologicheskiy zhurnal 2006; 6: 35-45. Russian (Бунин Ю.А., Федякина Л.Ф. Комбинированная профилактическая антиаритмическая терапия фибрилляции и трепетания предсердий. Российский кардиологический журнал 2006; 6: 35-45).
24. Dunn M.I. Thromboembolism with atrial flutter. Am J Cardiol 1998; 82: 638.
25. Seidl K., Hauer B., Schwick N.G. et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82(5): 580-583.
26. Halligan S.C., Gersh B.J., Brown R.D. The natural history of lone atrial flutter. Ann Intern Med 2004; 140(4): 265-268.
27. Feld G.K., Fleck R.P., Chen P.S. et al. Radiofrequency catheter ablation for the treatment of human type I atrial flutter. Circulation 1992; 86(4): 1233-1240.
28. Miller J.M., Zipes D.P. Therapy for cardiac arrhythmias. In: Braunwald E., Zipes D., LibbyP., Bonow R.,eds. Heart disease. A textbook of cardiovascular medicine. Philadelphia: W.B. Saunders company; 2005. p. 713-766.
29. Rho R.W., Callans D.J. The management of atrial flutter. In:Ganz L.I., Braunwald E.,eds. Management of cardiac arrhythmias. NJ: Humana Press;2004. p. 163-182.
30. Natale A., Newby K.H., Pisanу E.et al. Prospective randomized comparison of antiarrhythmic therapy versus first line radiofrequency ablation in patients with atrial flutter. J Am Coll Car-diol 2000; 35(7): 1898-1904.
31. Da Costa A., Thevenin J., Roche F. et al. Results from the Loire-Ardeche-Drome-Isere-Puyde-Dome (LADIP) trial. Circulation 2006; 114(16): 1676-1681.
32. Huang D.T., Monahan K.M., Zimetbaum P. et al. Hybrid pharmacologic and ablative therapy. J Cardiovasc Electrophysiol 1998;9(5):462-9.
33. Scheinman M.M., Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23(6): 1020-1028.